Researchers studying Alzheimer's disease increasingly rely on fluorescence microscopy to watch amyloid-beta (Aβ) plaques, tau aggregates, neuroinflammation and synaptic loss in living and fixed cell models. This article rounds up recent peer-reviewed discoveries that use EVOS fluorescence microscopy, GFP and RFP reporters, and explains how these tools fit into a UK research workflow. All papers are linked to their publisher or open repository.
Why GFP and RFP matter in Alzheimer's disease research
Green fluorescent protein (GFP) and red fluorescent protein (RFP) are genetically encoded tags that let scientists label proteins and track them inside cells. In Alzheimer's research they are commonly used to:
- Mark Aβ or tau expression in transgenic cell lines and organoids.
- Co-label mitochondria, lysosomes or autophagosomes to study cellular clearance pathways.
- Combine with calcium indicators or viability dyes to measure neuronal health in real time.
- Run high-content screening campaigns to test anti-aggregation compounds.
Benchtop fluorescence systems such as the Thermo Fisher EVOS M3000, M5000 and S1000 are popular in UK labs because they combine brightfield, phase and fluorescence in a compact enclosure, making them convenient for routine GFP/RFP imaging without booking a confocal slot.
1. Spatial biology maps how Aβ plaques age and drive synapse loss
Mei & Zhang et al., Nature Communications, September 2025.
The study uses isotope-encoded spatial biology to date amyloid plaques in an Alzheimer's mouse model and map how plaque age correlates with local synaptic loss. Older plaques sit at the centre of larger neighbourhoods of damaged synapses, while newer plaques cause less immediate harm. The work shows that not all plaques are equally toxic — plaque maturation state is a key variable.
For microscopy labs, the paper reinforces the value of combining fluorescent plaque labelling (often with GFP or RFP reporter lines such as APP/PS1-GFP) with spatial transcriptomics or high-resolution imaging to capture the tissue neighbourhood around each plaque.
Read the paper: Nature Communications.
Frequently asked questions about this study
Which platform was used to map plaque-age and synapse loss? The study used isotope-encoded spatial biology, which combines spatial transcriptomics with histological imaging. A fluorescence microscope such as the EVOS M5000 or S1000 can support the fluorescent plaque-labelling and tissue-section imaging that precedes spatial analysis.
Why does plaque age matter in Alzheimer’s disease? Older plaques are surrounded by larger zones of synaptic loss, while newer plaques cause less immediate damage. This suggests plaque maturation state could be a therapeutic target.
2. Split GFP assay screens for anti-tau aggregation drugs
Ibrahium et al., Scientific Reports, October 2025.
Tau aggregation into neurofibrillary tangles is a defining feature of Alzheimer's disease. The authors developed a split-GFP cell assay in which tau fragments reassemble GFP only when they come together, producing a fluorescent readout of tau oligomerisation. The assay is compatible with flow cytometry and fluorescence microscopy, making it suitable for medium-throughput drug screening.
This is exactly the kind of assay an EVOS system with GFP and RFP channels can image and quantify across multi-well plates. Because split-GFP signal scales with tau aggregation, researchers can measure compound effects by comparing total fluorescence per well — a straightforward readout for an GFP-capable microscope.
Read the paper: Scientific Reports.
Frequently asked questions about this study
Which platform is the split-GFP tau assay compatible with? The assay produces a GFP fluorescence readout that can be measured by flow cytometry or fluorescence microscopy. Benchtop systems such as the EVOS M3000, M5000 or S1000 can image and quantify the signal across multi-well plates.
How does split-GFP detect tau aggregation? Two non-fluorescent fragments of GFP are fused to tau. When tau molecules oligomerise, the fragments reassemble and restore GFP fluorescence, giving a quantitative aggregation signal.
3. Lipid rafts reveal how ApoE4 boosts Aβ production in human neurons
Lee et al., iScience, 2025.
The ApoE4 allele is the strongest genetic risk factor for late-onset Alzheimer's disease. Using live-cell fluorescence imaging of lipid rafts in human iPSC-derived neurons, the authors show that ApoE4 alters membrane cholesterol organisation in a way that increases amyloid precursor protein (APP) processing and Aβ production. The work links a well-known genetic risk factor to a visible membrane-level mechanism.
The experiments rely on fluorescent lipid raft probes and immunofluorescence for APP metabolites — techniques that translate directly to a widefield fluorescence microscope with stable illumination and good colour separation, such as an EVOS system with GFP and RFP filter sets.
Read the paper: iScience.
Frequently asked questions about this study
Which imaging technique showed ApoE4 increases Aβ production? Live-cell fluorescence imaging of lipid rafts in human iPSC-derived neurons, using fluorescent lipid-raft probes and immunofluorescence for APP metabolites. This maps directly onto the GFP/RFP capabilities of an EVOS fluorescence microscope.
Why is ApoE4 important in Alzheimer’s research? ApoE4 is the strongest genetic risk factor for late-onset Alzheimer’s disease. The paper links ApoE4 to altered membrane cholesterol organisation that increases amyloid precursor protein processing.
4. A microfluidic neurospheroid model of Alzheimer's pathophysiology
Molecular Brain, 2026.
Three-dimensional models are replacing flat monolayers in Alzheimer's research because they better replicate cell-cell signalling, nutrient gradients and Aβ diffusion. The paper describes a microfluidic neurospheroid grafted onto an endothelial barrier that recapitulates Aβ-induced blood-brain-barrier disruption and neuroinflammation. The model is designed for live-cell imaging and can be stained with fluorescent reporters for neurons, astrocytes and endothelial markers.
For labs considering a cell-culture microscope for long-term 3D AD models, the paper is a reminder that environmental control, stable focus and multi-channel fluorescence are more important than maximum magnification.
Read the paper: Molecular Brain.
Frequently asked questions about this study
What platform is best for imaging the neurospheroid model? The model is designed for live-cell imaging and fluorescent reporter visualisation. A cell-culture fluorescence microscope with environmental control, stable focus and multi-channel imaging — such as the EVOS M5000 or M7000 — is well suited to long-term 3D AD cultures.
What does the model recapitulate? Aβ-induced blood-brain-barrier disruption and neuroinflammation in a 3D microfluidic co-culture of neurons and endothelial cells.
5. Stress-altered extracellular vesicles sequester Aβ
Kumar et al., bioRxiv, May 2025.
This preprint reports that cellular stress changes the protein cargo of small extracellular vesicles (sEVs), enabling them to bind and sequester Aβ peptides. The finding suggests sEVs may be both a pathological vector and a potential therapeutic target in Alzheimer's disease. The work uses fluorescent labelling of Aβ and vesicle markers, imaging modalities that sit comfortably within the capability of a benchtop GFP/RFP fluorescence microscope for validation and quantification.
Read the preprint: bioRxiv.
Frequently asked questions about this study
Which imaging approach was used for extracellular vesicles? Fluorescent labelling of Aβ and vesicle markers, validated and quantified with fluorescence microscopy. This is within the routine GFP/RFP capability of an EVOS system.
How do extracellular vesicles relate to Alzheimer’s disease? The preprint suggests stress alters vesicle protein cargo so that vesicles bind and sequester Aβ, potentially acting as both a pathological vector and a therapeutic target.
How EVOS fluorescence microscopy fits the workflow
EVOS systems are not confocal microscopes, but they are well suited to the repetitive imaging steps that dominate Alzheimer's cell-biology research:
- Routine GFP/RFP checks — confirming reporter expression, transfection efficiency and cell health before expensive downstream assays.
- Plate-level quantification — imaging 96- or 384-well screens for Aβ or tau aggregation readouts after compound treatment.
- Time-lapse monitoring — following neurite outgrowth, synapse formation or cell death over hours to days in an on-stage incubator.
- Multi-channel overlays — combining GFP-labelled proteins with RFP-labelled organelles or viability dyes to build richer phenotypes.
The spectral-multiplex EVOS S1000 extends this further by unmixing up to four fluorescent channels without filter-cube swaps, which is useful when a project moves from simple GFP/RFP labelling to multi-marker panels.
What this means for UK Alzheimer's research labs
The 2025 literature shows Alzheimer's disease research moving toward:
- Higher-resolution spatial context — not just counting plaques, but mapping the cells and synapses around them.
- Genetically encoded reporters — GFP, RFP and split-GFP biosensors are becoming standard readouts for aggregation and pathway activity.
- 3D and microphysiological models — spheroids, organoids and microfluidic co-cultures that demand stable live-cell imaging.
- Scalable phenotypic screening — assays that need plate-level fluorescence quantification rather than single beautiful images.
For a UK lab choosing a fluorescence microscope for Alzheimer's disease work, the priority list should include reliable GFP/RFP excitation and emission filters, a stable mechanical stage for multi-well plate tiling, and software that can export intensity data for downstream analysis. Our GFP microscope buyer guide covers these requirements in detail.
Frequently asked questions
What is EVOS microscopy?
EVOS microscopy refers to the Invitrogen EVOS line of all-in-one cell-imaging systems from Thermo Fisher Scientific. They combine brightfield, phase-contrast and fluorescence imaging in a compact benchtop unit and are widely used in UK labs for routine GFP and RFP imaging.
What are GFP and RFP used for in Alzheimer's disease research?
GFP and RFP are fluorescent protein tags used to label amyloid-beta, tau, organelles and cellular structures in cell and organoid models. They allow researchers to track protein localisation, aggregation and cell health under a fluorescence microscope.
Can EVOS microscopes image live neurons over time?
Yes. EVOS systems can be fitted with on-stage environmental chambers for temperature and CO₂ control, making them suitable for live-cell imaging of neurons, astrocytes and organoids over hours to days.
What is the split-GFP tau aggregation assay?
The split-GFP tau assay uses two non-fluorescent fragments of GFP fused to tau. When tau molecules aggregate, the GFP fragments come together and restore fluorescence, producing a quantitative readout of tau oligomerisation suitable for drug screening.
How does spatial biology help Alzheimer's research?
Spatial biology maps gene expression and protein localisation within intact tissue sections. In Alzheimer's research it can reveal which cell types sit near plaques, how synapse density changes with plaque age, and how neuroinflammation spreads through tissue.
Which EVOS model is best for GFP and RFP multiplexing?
The EVOS M5000 and M7000 handle standard GFP/RFP two-colour imaging well. For projects moving to three- or four-colour panels, the EVOS S1000 offers spectral unmixing that reduces channel bleed-through.
Why are 3D models important in Alzheimer's disease studies?
Three-dimensional models such as neurospheroids and organoids recreate cell-cell signalling, nutrient gradients and Aβ diffusion more accurately than 2D monolayers. They are increasingly used to study plaque formation, tau propagation and blood-brain-barrier disruption.
References
- Mei Y, Zhang P et al. Isotope-encoded spatial biology identifies plaque-age-dependent maturation and synaptic loss in an Alzheimer's disease mouse model. Nature Communications. 2025;16:8916. https://www.nature.com/articles/s41467-025-63328-y
- Ibrahium OMH et al. A high-throughput drug screening assay for anti-tau aggregation using split GFP and flow cytometry. Scientific Reports. 2025;15:24758. https://www.nature.com/articles/s41598-025-21680-5
- Lee S-I et al. Imaging lipid rafts reveals the principle of ApoE4-induced Aβ upregulation in human neurons. iScience. 2025;28(3):111889. https://www.cell.com/iscience/fulltext/S2589-0042(25)00153-1
- Recapitulating Alzheimer's disease pathophysiology with a microfluidic neurospheroid-grafted endothelial barrier model. Molecular Brain. 2026;19:12. https://link.springer.com/article/10.1186/s13041-026-01285-3
- Kumar S, Nikolajeff F et al. Stress-induced alteration of small extracellular vesicles drives amyloid-beta sequestration and exacerbates Alzheimer's disease pathogenesis. bioRxiv. 2025. https://www.biorxiv.org/content/10.1101/2025.05.23.655679v2
- Klimaj S et al. A high-throughput imaging and quantification pipeline for the EVOS imaging platform. PLOS One. 2020;15(7):e0236397. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0236397